Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia
Status:
Not yet recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
This study will address the therapeutic activity and the safety/biological profile of
Ponatinib when used as third line therapy of Chronic Myeloid Leukemia in Chronic Phase after
the only two TKIs known for their cardiovascular safety, i.e. Imatinib and Bosutinib.
Phase:
Phase 2
Details
Lead Sponsor:
Associazione Italiana Pazienti Leucemia Mieloide Cronica